Biocryst Pharmaceuticals Stock Price Prediction

BCRX Stock  USD 7.60  0.11  1.47%   
At this time, The RSI of BioCryst Pharmaceuticals' share price is at 55 suggesting that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling BioCryst Pharmaceuticals, making its price go up or down.

Oversold Vs Overbought

55

 
Oversold
 
Overbought
The successful prediction of BioCryst Pharmaceuticals' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with BioCryst Pharmaceuticals, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting BioCryst Pharmaceuticals' stock price prediction:
EPS Estimate Next Quarter
(0.06)
EPS Estimate Current Year
(0.36)
EPS Estimate Next Year
(0.04)
Wall Street Target Price
14.6364
Quarterly Revenue Growth
0.35
Using BioCryst Pharmaceuticals hype-based prediction, you can estimate the value of BioCryst Pharmaceuticals from the perspective of BioCryst Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in BioCryst Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying BioCryst because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

BioCryst Pharmaceuticals after-hype prediction price

    
  USD 7.58  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out BioCryst Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
Intrinsic
Valuation
LowRealHigh
6.379.5312.69
Details
Naive
Forecast
LowNextHigh
4.297.4510.61
Details
11 Analysts
Consensus
LowTargetHigh
13.8315.2016.87
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.1-0.09-0.07
Details

BioCryst Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of BioCryst Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in BioCryst Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of BioCryst Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

BioCryst Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting BioCryst Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on BioCryst Pharmaceuticals' historical news coverage. BioCryst Pharmaceuticals' after-hype downside and upside margins for the prediction period are 4.42 and 10.74, respectively. We have considered BioCryst Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
7.60
7.58
After-hype Price
10.74
Upside
BioCryst Pharmaceuticals is somewhat reliable at this time. Analysis and calculation of next after-hype price of BioCryst Pharmaceuticals is based on 3 months time horizon.

BioCryst Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as BioCryst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioCryst Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BioCryst Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.07 
3.16
  0.02 
 0.00  
8 Events / Month
17 Events / Month
In about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
7.60
7.58
0.26 
987.50  
Notes

BioCryst Pharmaceuticals Hype Timeline

BioCryst Pharmaceuticals is currently traded for 7.60. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.0. BioCryst is projected to decline in value after the next headline, with the price expected to drop to 7.58. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.26%, whereas the daily expected return is currently at -0.07%. The volatility of related hype on BioCryst Pharmaceuticals is about 26738.46%, with the expected price after the next announcement by competition of 7.60. About 86.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.61. BioCryst Pharmaceuticals had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 8 days.
Check out BioCryst Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

BioCryst Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to BioCryst Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict BioCryst Pharmaceuticals' future price movements. Getting to know how BioCryst Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how BioCryst Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
TGTXTG Therapeutics 0.60 8 per month 3.15  0.12  7.62 (4.62) 24.51 
AXSMAxsome Therapeutics 0.66 8 per month 1.89  0.04  4.10 (3.78) 13.67 
ICPTIntercept Pharmaceuticals 0.66 3 per month 0.00 (0.17) 5.23 (8.32) 38.17 
MCRBSeres Therapeutics(0.06)9 per month 5.68 (0.02) 10.00 (9.78) 28.84 
MDGLMadrigal Pharmaceuticals(3.37)8 per month 2.09  0.10  5.17 (3.96) 30.27 
KZRKezar Life Sciences 0.33 9 per month 3.01  0.06  8.11 (4.39) 51.13 
IMUXImmunic(0.05)11 per month 0.00 (0.13) 5.71 (6.84) 23.75 
ATRAAtara Biotherapeutics 0.12 9 per month 4.69  0.11  19.77 (10.39) 44.50 
PIRSPieris Pharmaceuticals 0.25 5 per month 0.00 (0.11) 3.23 (3.40) 12.92 
APLSApellis Pharmaceuticals 2.68 8 per month 0.00 (0.13) 4.31 (5.17) 15.97 
BPMCBlueprint Medicines Corp 3.17 10 per month 2.61 (0.03) 4.90 (3.62) 14.28 
KRTXKaruna Therapeutics 0.00 0 per month 1.67 (0.04) 3.38 (2.71) 10.01 
MRTXMirati Ther 0.00 0 per month 0.00 (0.18) 4.02 (4.07) 16.13 
DAWNDay One Biopharmaceuticals 0.23 9 per month 2.72 (0.04) 3.84 (3.69) 11.44 
AVXLAnavex Life Sciences(0.55)8 per month 3.39  0.12  10.31 (7.22) 30.62 
SAVACassava Sciences(1.29)10 per month 0.00 (0.03) 9.51 (8.62) 21.05 
INMBINmune Bio 0.22 9 per month 0.00 (0.10) 5.78 (7.10) 22.66 
BIVIBiovie Inc(1.47)9 per month 10.68  0.06  11.91 (9.39) 133.33 
CGTXCognition Therapeutics 0.04 8 per month 0.00 (0.13) 8.89 (10.34) 36.32 
VKTXViking Therapeutics(1.86)9 per month 0.00 (0.07) 6.24 (8.05) 34.61 
XFORX4 Pharmaceuticals 0.02 7 per month 0.00 (0.08) 6.90 (10.61) 62.35 
PDSBPDS Biotechnology Corp(0.07)10 per month 0.00 (0.15) 7.67 (6.76) 31.83 

BioCryst Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine BioCryst price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for BioCryst using various technical indicators. When you analyze BioCryst charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About BioCryst Pharmaceuticals Predictive Indicators

The successful prediction of BioCryst Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as BioCryst Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of BioCryst Pharmaceuticals based on analysis of BioCryst Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to BioCryst Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to BioCryst Pharmaceuticals's related companies.
 2021 2022 2023 2024 (projected)
Graham Number12.4815.37.936.31
Receivables Turnover5.345.355.822.98

Story Coverage note for BioCryst Pharmaceuticals

The number of cover stories for BioCryst Pharmaceuticals depends on current market conditions and BioCryst Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that BioCryst Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about BioCryst Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

BioCryst Pharmaceuticals Short Properties

BioCryst Pharmaceuticals' future price predictability will typically decrease when BioCryst Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of BioCryst Pharmaceuticals often depends not only on the future outlook of the potential BioCryst Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioCryst Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding192.2 M
Cash And Short Term Investments390.8 M

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.